A study led by experts at Johns Hopkins and published in JAMA found that the Food and Drug Administration’s decisions about the abortion pill mifepristone from 2011 to 2023 almost always followed evidence-based recommendations from the agency’s scientists. The researchers obtained 264 documents totaling 5,239 pages through